AstraZeneca vaccine: Dr Green shares what's in Oxford jab
We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info
The speed and success of the Covid vaccination campaign across the rich world has been breathtaking. Legitimate ethical concerns have been raised around the uneven distribution but plunging death rates in developed countries is a testament to both scientific ingenuity and efficient public health policy. However, the effects of the vaccines must be monitored, even though getting vaccinated is a no brainer for the vast majority of the population.
New side effects continue to spring up as the vaccines make their way into different populations.
Now the European Medicines Agency (EMA) has issued an update about the AstraZeneca Covid vaccine.
“A warning to raise awareness of cases of Guillain-Barré syndrome (GBS) reported following vaccination was included in the product information of Vaxzevria following PRAC in July 2021,” the EMA stated in a release on Monday.
The Pharmacovigilance Risk Assessment Committee (PRAC) is the European Medicines Agency’s (EMA) committee responsible for assessing and monitoring the safety of human medicines.
PRAC has been keeping GBS under close monitoring and in September 2021 assessed additional data requested from the marketing authorisation holder and the results from a scientific literature review.
GBS is a serious nerve inflammation, which may cause temporary loss of feeling and movement (paralysis) and difficulty breathing.
It is important to put the risk into perspective.
A total of 833 cases of GBS had been reported with the AstraZeneca vaccine worldwide by 31 July 2021, while around 592 million doses of AstraZeneca vaccine had been given to people worldwide by 25 July 2021.
High blood pressure: Three drinks to reduce reading [TIPS]
Cancer: Vitamin deficiency common in patients [INSIGHT]
Diabetes type 2: The herb to lower high blood sugar [ADVICE]
Reported cases concern suspected side effects, i.e. medical events that have been observed after vaccination, but which are not necessarily related to or caused by the vaccine.
The EMA concluded: “Based on the assessment of these data and taking into account neurological expert advice, PRAC concluded that a causal relationship between Vaxzevria [AstraZeneca vaccine] and GBS is considered at least a reasonable possibility.”
According to the NHS, GBS mainly affects the feet, hands and limbs, causing problems such as numbness, weakness and pain.
“It can be treated and most people will eventually make a full recovery, although it can occasionally be life-threatening and some people are left with long-term problems,” warns the health body.
As it explains, GBS affects people of all ages but it is more common in adults and males.
At first you may have:
- Pins and needles
- Muscle weakness
- Problems with balance and coordination.
Why the latest update shouldn’t deter you from getting vaccinated
Hundreds of millions of people have had a coronavirus (COVID-19) vaccine and the safety of the vaccines continues to be monitored.
Reports of serious side effects are very rare.
COVID-19 vaccines have to go through several stages of clinical trials before they can be approved for use.
Clinical trials are where a vaccine or medicine is tested on volunteers to make sure it works and is safe.
All vaccines used in the UK must be approved by the independent Medicines and Healthcare products Regulatory Agency (MHRA).
The MHRA makes sure the vaccines meet strict international standards for safety, quality and effectiveness. Once a vaccine is approved, it’s closely monitored to continue to make sure it is safe and effective.
Source: Read Full Article